InsidersTradesSigma
Track the ESTABLISHMENT LABS HOLDINGS INC. share price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, ESTABLISHMENT LABS HOLDINGS INC. has published 9 reports. Market capitalisation: €2.2bn. The latest transaction was disclosed on 26 August 2026 (Retenue fiscale). Among the most active insiders: SCHUTTER EDWARD J. The full history is accessible without an account.
9
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ESTABLISHMENT LABS HOLDINGS INC. Strong Buy (bullish), based on 9 analysts. Average price target: US$102.44.
Fundamental score
Ranked 23,878 of 29,063 companies
29.1
score / 100
Value27
Quality31
FCF yld-2.8%
Earn yld-2.5%
EV/EBITDA·
ROE-175%
Gross mgn69%
Net mgn-24%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 26 August 2026
Declarations9 total
682 shares@ US$71.52Common SharesSEC:0001839059-26-000006:0
291 sharesCommon SharesSEC:0001398327-26-000005:0
189 sharesCommon SharesSEC:0001861660-26-000005:0
196 sharesCommon SharesSEC:0001862601-26-000005:0
216 sharesCommon SharesSEC:0001254555-26-000006:0
1,949 sharesCommon SharesSEC:0001628280-26-046089:0
1,281 sharesCommon SharesSEC:0001628280-26-046089:1
59,198 shares0Common SharesSEC:0001628280-25-030539:0
73,371 shares0Common SharesSEC:0001254555-25-000004:0
9 of 9 declarations
关于 ESTABLISHMENT LABS HOLDINGS INC.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) 是一家总部位于美国的医疗技术公司，其商业模式以女性健康为中心，特别是乳房美学和乳房重建。该公司由 Juan José Chacón-Quirós 创立，在哥斯达黎加建立了其工业基地，其运营总部和主要制造能力位于阿拉胡埃拉。Establishment Labs 已发展成为一家全球性企业，产品销往 100 多个国家，并直接向整形和重建外科医生以及其他医疗保健提供者销售产品。（[investors.establishmentlabs.com](https://investors.establishmentlabs.com/press-releases/press-releases-details/2025/Establishment-Labs-to-Present-at-the-43rd-Annual-J.P.-Morgan-Healthcare-Conference/default.aspx?utm_source=openai)） 该公司的核心业务是 Motiva 系列硅胶乳房植入物及相关的乳房健康解决方案。其产品组合包括 SmoothSilk 和 Ergonomix 等专有技术，旨在增强生物相容性、柔软度以及对身体运动更自然的反应。随着时间的推移，Establishment Labs 已从标准植入物扩展到更具差异化的微创平台，包括 Mia Femtech 和 Preservé，以及用于乳房重建的组织扩张器 Motiva Flora。这种组合使该公司在美学和重建手术这两个具有吸引力长期需求驱动因素的市场中占据一席之地。（[investors.establishmentlabs.com](https://investors.establishmentlabs.com/press-releases/press-releases-details/2025/Establishment-Labs-Launches-Preserv/default.aspx?utm_source=openai)） 从竞争角度来看，Establishment Labs 将自己定位为由创新驱动的挑战者，在一个历史上由大型传统参与者主导的类别中脱颖而出。其在美国的监管进展是一个重要的战略里程碑：FDA 对 Motiva 的批准帮助其打开了最大的医疗设备市场，并增强了品牌在外科医生和患者中的信誉。美国市场的商业势头现在已在报告的季度业绩中显现，随着公司扩大其国内市场，Motiva 在美国的销售额不断增长。（[investors.establishmentlabs.com](https://investors.establishmentlabs.com/press-releases/press-releases-details/2024/Establishment-Labs-Receives-U.S.-FDA-Approval-for-Motiva-Implants/default.aspx?utm_source=openai)） 近期消息是积极的。2025 年，该公司在巴西推出了 Preservé 并继续在全球推广，同时报告收入趋势改善并上调了业绩指引。2026 年初，季度收入进一步增长，管理层上调了全年预期。该公司还在 2026 年 4 月宣布，已在市场投放超过 5 million 个 Motiva 设备，这突显了其商业渗透率和长期安装基础的增长。对于投资者而言，ESTA 最好的视角是将其视为一个由产品创新、地域扩张和监管执行驱动的纳斯达克上市的美国医疗保健成长型故事。（[investors.establishmentlabs.com](https://investors.establishmentlabs.com/press-releases/press-releases-details/2025/Establishment-Labs-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Reaffirms-2025-Guidance/default.aspx?utm_source=openai)）
